CapsoVision director buys 20 company shares

CapsoVision, Inc director Tsai Chen Lung reported an open-market purchase of common stock.

Rhea-AI Filing Summary

CapsoVision, Inc director Tsai Chen Lung reported an open-market purchase of common stock. A joint brokerage account for Tsai and his wife bought 20 shares of CapsoVision common stock at $4.17 per share on July 3, 2025. This Form 4/A is an amendment, filed because the transaction was inadvertently omitted from the original Form 4 submitted on July 7, 2025. After this trade, the account held 20 shares directly.

Insider Trade Summary

Net Buyer: 20 shares

Net Buy 1 txn

Insider Tsai Chen Lung

Role Director

Bought 20 shs ($83.40)

Type	Security	Shares	Price	Value
Purchase	Common Stock	20	$4.17	$83.40

Holdings After Transaction: Common Stock — 20 shares (Direct)

Footnotes (1)

1. F1. Held by the Reporting Person and his wife in a joint brokerage account. The transaction was inadvertently omitted from the original Form 4 filed on July 7, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CapsoVision (CV) director Tsai Chen Lung report?

CapsoVision director Tsai Chen Lung reported an open-market purchase of 20 shares of common stock at $4.17 per share. The shares are held in a joint brokerage account with his wife, and the filing updates prior disclosure to include this previously omitted trade.

When did the reported CapsoVision (CV) insider trade occur?

The insider trade occurred on July 3, 2025, when a joint brokerage account for director Tsai Chen Lung and his wife purchased 20 CapsoVision common shares at $4.17 each. This Form 4/A corrects the record by adding a transaction missing from the original filing.

How many CapsoVision (CV) shares did the insider buy and at what price?

The insider transaction involved the purchase of 20 CapsoVision common shares at $4.17 per share. These shares are reported as held directly in a joint brokerage account shared by director Tsai Chen Lung and his wife following the July 3, 2025 open-market transaction.

Why was this CapsoVision (CV) Form 4/A amendment filed?

The Form 4/A was filed because the July 3, 2025 purchase of 20 CapsoVision shares at $4.17 per share was inadvertently omitted from the original Form 4 filed on July 7, 2025. The amendment updates the insider ownership record to include this transaction.

Who holds the CapsoVision (CV) shares from this insider transaction?

The 20 CapsoVision common shares from this transaction are held in a joint brokerage account owned by director Tsai Chen Lung and his wife. The filing reports the holding as direct ownership, bringing total directly held shares to 20 following the July 3, 2025 purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tsai Chen Lung

(Last) (First) (Middle)

C/O CAPSOVISION, INC.

18805 COX AVENUE, SUITE 250

(Street)

SARATOGA CA 95070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CapsoVision, Inc [ CV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/03/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/03/2025		P		20	A	$4.17	20	D(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Held by the Reporting Person and his wife in a joint brokerage account. The transaction was inadvertently omitted from the original Form 4 filed on July 7, 2025.

Remarks:

	/s/ Kang-Huai (Johnny) Wang, Attorney-in-Fact for Tsai Chen Lung	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.